Geron, Sucampo Pharmaceuticals, and Inogen might be three hidden gems in the healthcare sector.
News & Analysis: Sucampo Pharmaceuticals
The company reported full-year 2016 financial results.
A new debt offering was announced, but the market appears to be overreacting.
Investors interpreted the results of the general election as favorable to the industry, but a few stocks reported other news today as well.
The potential to double always comes with risk, but these stocks could give investors incredible returns.
With PEG ratios well below one, these small-cap value stocks could be screaming buys.
These three growth stocks are cheap now, but they might not stay cheap for much longer.
Sucampo shares hit the deck, at least briefly, after reporting its first-quarter results. Find out if this dip is a buying opportunity for investors or a reason to keep your distance.
Sucampo shares are off to the races after topping Wall Street's profit expectations in the fourth-quarter. Is this earnings beat meaningful or just white noise?
Sucampo's 8-K filing with the SEC delivers a nice surprise to shareholders.